AHA 2019 ICYMI: Summaries of 11 late-breaking clinical trials presented at the 2019 Scientific Sessions held in Philadelphia, PA, Nov 16-18.
COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types
Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Recent Recreational Drug Use Ups Risk of Repeat Serious CV Event: Daily Dose
Your daily dose of the clinical news you may have missed.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
Finerenone Improves Outcomes in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction
ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.
Recreational Drug Users Face Triple the Risk of Repeat Major Adverse CV Events vs Non-Users
ESC 2024: Cannabis, opioid, and MDMA use were most strongly tied to cardiovascular event risk, according to a new study.